Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA

被引：0

作者：

Decker, Thomas

Brucker, Cosima

Engel, Anne

Fasching, Peter A.

Goehler, Thomas

Jackisch, Christian

Janssen, Jan

Koehler, Andreas

Luedtke-Heckenkamp, Kerstin

Lueftner, Diana

van Mackelenbergh, Marion

Marme, Frederik

Nusch, Arnd

Rautenberg, Beate

Reimer, Toralf

Schmidt, Marcus

Weide, Rudolf

Wimberger, Pauline

Roos, Christian

Woeckel, Achim

机构：

[1] Onkol Ravensburg, Ravensburg, Germany

[2] Paracelsus Med Univ, Univ Womens Hosp, Nurnberg, Germany

[3] Winicker Norimed GmbH, Nurnberg, Germany

[4] Univ Hosp Erlangen, Dept Obstet & Gynecol, Erlangen, Germany

[5] Onkozentrum Dresden Freiberg, Dresden, Germany

[6] Sana Klinikum Offenbach, Dept Obstet & Gynecol, Offenbach, Germany

[7] Med Studiengesell Nord West GmbH, Westerstede, Rhauderfehn, Germany

[8] Practice Hematol & Oncol, Langen, Germany

[9] Niels Stensen Kliniken, Dept Hematol & Oncol, Georgsmarienhutte, Germany

[10] Med Univ Brandenburg, Immanuel Klin Markische Schweiz, Buckow, Germany

[11] Univ Klinikum Schleswig Holstein, Kiel, Germany

[12] Heidelberg Univ, Med Fak Mannheim, Mannheim, Germany

[13] Practice Hematol & Internal Oncol, Velbert, Germany

[14] Univ Klinikum Freiburg, Freiburg, Germany

[15] Univ Klinikum Rostock, Rostock, Germany

[16] Johannes Gutenberg Univ Mainz, Klin & Poliklin Geburtshilfe & Frauengesundheit, Mainz, Germany

[17] InVO GbR, Koblenz, Germany

[18] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Dresden, Germany

[19] Novartis Pharma GmbH, Nurnberg, Germany

[20] Univ Wurzburg, Dept Gynecol & Obstet, Wurzburg, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e13050

引用

页数：1

共 50 条

[11] RIBOCICLIB (RIB) plus LETROZOLE (LET) IN OLDER PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC): SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL
De Laurentiis, Michelino
Campone, Mario
Alba Conejo, Emilio
Tanner, Minna
Egle, Daniel
Papai, Zsuzsanna
Prat Aparicio, Aleix
Dent, Susan
Warner, Ellen
Ankrah, Nii
Wu, Jiwen
Zhou, Katie
Borstnar, Simona
BREAST, 2019, 48 : S46 - S47
[12] Real-world efficacy of ribociclib plus aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Second interim analysis from the RIBANNA study
Woeckel, Achim
Basiora, Pawel
Bohlmann, Michael
Decker, Thomas
Falbrede, Joerg
Fasching, Peter
Forstbauer, Helmut
Hesse, Tobias
Hoffmann, Oliver
Jackisch, Christian
Kaczerowsky, Anna
Lorenz, Ralf
Luedtke-Heckenkamp, Kerstin
Lueftner, Diana
Marme, Frederik
Mueller, Thomas
Mundhenke, Christoph
Nusch, Arnd
Petersen, Volker
Prange-Krex, Gabriele
Reimer, Toralf
Resch, Thomas
Roos, Christian
Tome, Oliver
Weishap, Anja
CANCER RESEARCH, 2020, 80 (04)
[13] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial
Lu, Janice
Cottu, Paul
Martin, Miguel
Zamagni, Claudio
Prat, Aleix
Chia, Stephen
Jerusalem, Guy
Rajappa, Senthil
Timcheva, Constanta
Zhukova, Lyudmila
Zhou, Katie
Wu, Jiwen
Menon-Singh, Lakshmi
De Laurentiis, Michelino
CANCER RESEARCH, 2021, 81 (04)
[14] Real-world treatment durations without chemotherapy (CT) for hormone-receptor-positive (HR plus )/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC)
Swallow, Elyse
Wang, Jenny
Thomason, Darren
Tan, Ruo-Ding
Kageleiry, Andrew
Signorovitch, James
CANCER RESEARCH, 2015, 75
[15] The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC).
Chainitikun, Sudpreeda
Long, James
Rodriguez-Bautista, Ruben
Iwase, Toshiaki
Tripathy, Debu
Fujii, Takeo
Ueno, Naoto T.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[16] Ribociclib (RIBO) plus letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
Abdel-Razeq, H.
Cottu, P. H.
Ring, A.
De laurentiis, M.
Lu, J.
Azim, H. A.
Zamagni, C.
Zhou, K.
Wu, J.
Menon, L.
Martin, M.
ANNALS OF ONCOLOGY, 2018, 29
[17] Ribociclib (RIBO) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
Zamagni, C.
Campone, M.
Kudryavcev, I.
Brown-Glaberman, U.
Cottu, P. H.
Ring, A.
Lu, J.
Martin, M.
De laurentiis, M.
Zhou, K.
Wu, J.
Menon, L.
Azim, H. A.
ANNALS OF ONCOLOGY, 2018, 29
[18] First-line ribociclib plus letrozole in postmenopausal Asian women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2
Yap, Y. S.
Tseng, L-M.
Blackwell, K. L.
Cameron, D.
Foo, S.
Sriuranpong, V.
Huang, C-S.
Chao, T-Y.
Kim, T-Y.
Chen, S-C.
Jung, K. H.
Lee, K. S.
Sohn, J-H.
Kim, J. H.
Hou, M-F.
Han, Y.
Souami, F.
Dhuria, S.
Miller, M.
Verma, S.
ANNALS OF ONCOLOGY, 2016, 27
[19] Ribociclib (RIB) plus letrozole (LET) in Asian patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2L-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
Chatterjee, S.
Yusof, M. Md
Dejthevaporn, T.
Chung, W-P.
Galvez, C. G.
Sunpaweravong, P.
Cheng, A.
Abesamis-Tiambeng, M. L. T.
Michelle, S. O. Y.
Menon-Singh, L.
Wu, J.
Zhou, K.
Azim, H.
ANNALS OF ONCOLOGY, 2020, 31 : S1260 - S1261
[20] Poster Discussion Session Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/ human epidermal growth factor receptor-negative (HR+/HER2-) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC).
Rugo, Hope S.
O'Shaughnessy, Joyce
Jhaveri, Komal L.
Tolaney, Sara M.
Cardoso, Fatima
Bardia, Aditya
Maheshwari, Vikalp Kumar
Tripathi, Sandeep
Pathak, Purnima
Haftchenary, Sina
Fasching, Peter A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →